Clinical trial NCT04170023: Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy
Official title: A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ALXN2050 (ACH-0145228) in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients as Monotherapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Keywords: paroxysmal nocturnal hemoglobinuria
PNH
extravascular hemolysis
EVH
factor D inhibitor
complement
C5 inhibitor
danicopan
Lead sponsor: Alexion Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2019-11-20
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study will evaluate the efficacy and safety of the oral Factor D (FD) inhibitor ALXN2050 (ACH-0145228) monotherapy in patients with PNH that are treatment naïve, or patients currently treated with eculizumab who still experience anemia and reticulocytosis, or patients currently treated with ALXN2040 (danicopan) as monotherapy. After signing consent, participants will have periodic visits through Week 12, at which time the primary endpoint and key secondary assessments will be analyzed. Participants will continue on treatment past 12 weeks into a long-term extension portion of the trial.

Detailed description: Experimental: Open-label ALXN2050 Monotherapy orally

Group 1: Patients with PNH who are treatment naïve

Group 2: Patients with PNH who have received complement component 5 (C5) inhibition with eculizumab for at least 6 months, who continue to experience anemia and reticulocytes above the upper limit of normal (ULN) who will switch to ALXN2050 monotherapy

Group 3: Patients with PNH receiving danicopan monotherapy in study ACH471-103 will switch to ALXN2050 monotherapy

After signing the informed consent form, participants will enter the screening period. During the Screening Period, eligibility and screening assessments will be performed. Screening assessments may be spread over more than one visit if necessary. At the baseline visit, screened participants who continue to meet eligibility criteria will enter the Treatment Period.

The treatment phase will be followed by a long-term extension phase, where ALXN2050 will continue to be administered.

Blood will be collected to assess the efficacy endpoints, such as, change in hemoglobin (Hgb), lactate dehydrogenase (LDH), and other measures of hemolysis. Safety and transfusion requirements will also be assessed.

Participants will continue on treatment past 12 weeks in a long-term extension portion of the trial.

Eligibility criteria: Key Inclusion Criteria:

1. Diagnosis of PNH.
2. Male or female, ≥ 18 years of age

Eligibility Criteria:

Eligibility Criteria Specific for Group 1:

1. PNH Patients who have no history of treatment with any complement inhibitor at any dose.
2. PNH Type III erythrocyte or granulocyte clone size ≥10%
3. Absolute reticulocyte count ≥100×10\^9/liter \[L\].
4. Anemia (Hgb \<10.5 grams/deciliter \[g/dL\]).
5. LDH ≥1.5× upper limit of normal.
6. Platelet count ≥30,000/microliter (µL)
7. Absolute neutrophil count (ANC) ≥750/ µL.

Eligibility Criteria Specific for Group 2:

1. Stable background regimen of at least 24 weeks for eculizumab without change in dose or interval for at least the past 8 weeks
2. Anemia (Hgb \<10 g/dL)
3. Absolute reticulocyte count ≥100×10\^9/L
4. Platelet count ≥30,000/µL
5. Absolute neurophil count (ANC) ≥750/ µL

Eligibility Criteria Specific for Group 3:

1. Patient received danicopan during Study ACH471-103

Key Exclusion Criteria:

1. History of a major organ transplant or hematopoietic stem cell/marrow transplant .
2. Known aplastic anemia or other bone marrow failure that requires HSCT, or if these patients are on immunosuppressive agents for less than 24 weeks.
3. Known underlying bleeding disorders or any other conditions leading to anemia not primarily associated with PNH.
4. Estimated glomerular filtration rate \<30 milliliters/minute/1.73 meters squared and/or are on dialysis.

Primary outcomes:
measure: Change From Baseline in Hgb at Week 12
timeFrame: Baseline, Week 12
Secondary outcomes:
measure: Number of Participants Who Had Transfusion Avoidance During 12 Weeks of Treatment With ALXN2050
timeFrame: Baseline up to Week 12
measure: Number of Red Blood Cell (RBC) Units Transfused During 12 Weeks of Treatment
timeFrame: Baseline up to Week 12
measure: Number of Transfusion Instances During 12 Weeks of Treatment
timeFrame: Baseline up to Week 12
measure: Change From Baseline in Lactate Dehydrogenase (LDH) at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Absolute Reticulocyte Count at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Direct and Total Bilirubin at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Clone Size at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Component 3 (C3) Fragment Deposition on PNH RBCs at Week 12
timeFrame: Baseline, Week 12
measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Events Leading to Discontinuation of Study Medication
timeFrame: From first dose of study drug up to Week 217
measure: Change From Baseline in Hgb at the End of Treatment (EOT) During the LTE Period
timeFrame: Baseline, EOT visit (Maximum exposure: 213.4 weeks)
measure: Change From Baseline in LDH at the EOT During the LTE Period
timeFrame: Baseline, EOT visit (Maximum exposure: 213.4 weeks)
measure: Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale (Version 4) Total Score at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in FACIT-Fatigue Scale (Version 4) Total Score at the EOT During the LTE Period
timeFrame: Baseline, EOT visit (Maximum exposure: 213.4 weeks)
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Research Site
state: Ontario
city: Levis
country: Canada
facility: Research Site
state: Quebec
city: Avellino
country: Italy
facility: Research Site
city: Firenze
country: Italy
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Christchurch
country: New Zealand
facility: Research Site
city: Grafton
country: New Zealand
facility: Research Site
city: Albacete
country: Spain
facility: Research Site
city: Istanbul
country: Turkey
facility: Research Site
city: Izmir
country: Turkey
facility: Research Site
city: London
country: United Kingdom
facility: Research Site
Study officials:
References: